HomeCompareIKNX vs ORCC

IKNX vs ORCC: Dividend Comparison 2026

IKNX yields 2.97% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IKNX wins by $2.8K in total portfolio value· pulled ahead in Year 3
10 years
IKNX
IKNX
● Live price
2.97%
Share price
$33.90
Annual div
$1.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.2K
Annual income
$359.58
Full IKNX calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — IKNX vs ORCC

📍 IKNX pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIKNXORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IKNX + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IKNX pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IKNX
Annual income on $10K today (after 15% tax)
$252.41/yr
After 10yr DRIP, annual income (after tax)
$305.64/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, IKNX beats the other by $304.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IKNX + ORCC for your $10,000?

IKNX: 50%ORCC: 50%
100% ORCC50/50100% IKNX
Portfolio after 10yr
$22.8K
Annual income
$180.31/yr
Blended yield
0.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

IKNX
No analyst data
Altman Z
0.6
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IKNX buys
0
ORCC buys
18
PoliticianChamberTickerTypeAmountDate
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-23
Trey Hollingsworth🏢 House$ORCC▲ Buy$250,001 - $500,0002022-06-16
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-14
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-13
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-10
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-09
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-06-08
Trey Hollingsworth🏢 House$ORCC▲ Buy$50,001 - $100,0002022-06-03
Trey Hollingsworth🏢 House$ORCC▲ Buy$15,001 - $50,0002022-05-24
Trey Hollingsworth🏢 House$ORCC▲ Buy$100,001 - $250,0002022-05-20
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIKNXORCC
Forward yield2.97%9.79%
Annual dividend / share$1.01$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$24.2K$21.4K
Annual income after 10y$359.58$1.04
Total dividends collected$3.3K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: IKNX vs ORCC ($10,000, DRIP)

YearIKNX PortfolioIKNX Income/yrORCC PortfolioORCC Income/yrGap
1$10,997$296.95$11,190$489.61$193.00ORCC
2$12,072$305.19$12,229$256.01$157.00ORCC
3← crossover$13,230$313.11$13,216$130.74+$14.00IKNX
4$14,477$320.70$14,207$66.02+$270.00IKNX
5$15,818$327.96$15,234$33.17+$584.00IKNX
6$17,260$334.91$16,317$16.62+$943.00IKNX
7$18,810$341.53$17,468$8.32+$1.3KIKNX
8$20,475$347.85$18,695$4.16+$1.8KIKNX
9$22,262$353.86$20,006$2.08+$2.3KIKNX
10$24,180$359.58$21,407$1.04+$2.8KIKNX

IKNX vs ORCC: Complete Analysis 2026

IKNXStock

IKONICS Corp. engages in the development, manufacture, and trade of photochemical imaging products. The company is headquartered in Duluth, Minnesota and currently employs 75 full-time employees. The firm has five operating segments: Domestic, Export, IKONICS Imaging, Digital Texturing (DTX) and Advanced Material Solutions (AMS). Domestic segment sells screen printing film, emulsions, and inkjet receptive film to distributors located in the United States and Canada. IKONICS Imaging segment sells photo resistant film, art supplies, glass, metal medium and related abrasive etching equipment. AMS segment provides sound deadening technology to the aerospace industry along with products and services for etched composites, ceramics, glass and silicon wafers. DTX segment includes products and customers related to inkjet technology used for mold texturing and prototyping. Export segment sells primarily the same products as Domestic and the IKONICS Imaging products not related to AMS or DTX.

Full IKNX Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this IKNX vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IKNX vs SCHDIKNX vs JEPIIKNX vs OIKNX vs KOIKNX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.